Research

Hormonal

Semaglutide treatment reduces plasma levels of FABP4 and modulates neutrophil phenotype (increasing CD88, reducing CD11b-mediated adhesion), thereby attenuating prothrombotic and atherosclerotic mechanisms.

For patients with Type 2 Diabetes and obesity who are not controlled on oral medications, Semaglutide (0.5-1.0 mg weekly) not only aids weight loss but may also reduce specific cardiovascular risk markers like FABP4 and improve neutrophil behavior, potentially lowering atherosclerosis risk. This benefit is observed after 6 months of treatment.

ModerateSupportsMEDIUM confidence
Monocytes and neutrophils phenotype and plasma adiposity, stretch, mesothelial, fibrotic, and inflammatory markers on patients underwent semaglutide treatment for 6 months showed a 20% reduction with statistical significance on FABP4 levels and an 80% increase of neutrophils-CD88.
David García‐Vega et al. · Cardiovascular Diabetology · 2024

Why this rating

Observational longitudinal study with a small sample size (n=21) and no control group, though supported by mechanistic in-vitro data.

Source

Semaglutide modulates prothrombotic and atherosclerotic mechanisms, associated with epicardial fat, neutrophils and endothelial cells network

David García‐Vega et al. · Cardiovascular Diabetology · 2024

DOI 10.1186/s12933-023-02096-9

cohort · n=21Cited 49×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →